Miscellaneous| Volume 111, ISSUE 5, P760-764, March 01, 2013

Biomarkers and Electrocardiographic Evidence of Myocardial Ischemia in Patients With Human Immunodeficiency Virus Infection

Published:January 07, 2013DOI:
      We assessed the relation of inflammatory and coagulation biomarkers with electrocardiographic (ECG) evidence of myocardial ischemia. High-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), and D-dimer levels were measured at study entry for 3,085 human immunodeficiency virus-infected participants (mean age 44 years; 26.4% women; 24.6% black) in the Strategies for Management of Antiretroviral Therapy trial. Logistic regression models were used to examine the associations of these biomarkers with prevalent and incident myocardial ischemia. The latter analyses were performed for 1,411 participants who were randomly assigned to receive continuous antiretroviral therapy during follow-up to suppress the human immunodeficiency virus viral load and had ≥1 ECG reading during the follow-up period. The median hsCRP, IL-6, and D-dimer level was 1.65 μg/ml (interquartile range 0.69 to 4.11), 1.60 pg/ml (interquartile range 1.00 to 2.75), and 0.18 μg/ml (interquartile range 0.11 to 0.32), respectively. At baseline, the prevalence of major or minor Q-QS or ST-T ECG abnormalities was 18.6%. The biomarker levels were associated with prevalent major or minor ischemic abnormalities on the univariate analyses; however, adjustment for traditional risk factors attenuated these associations. The adjusted odds ratio for major or minor ischemic abnormalities and 95% confidence intervals for the greatest versus lowest quartiles was 1.3 (95% confidence interval 0.9 to 1.7) for hsCRP, 1.0 (95% confidence interval 0.7 to 1.3) for IL-6, and 1.1 (95% confidence interval 0.9 to 1.5) for D-dimer. During a median follow-up of 2.3 years, new definite or probable ischemic ECG abnormalities developed in 11.7% of participants receiving continuous antiretroviral therapy. Biomarker levels were not associated with incident abnormalities on unadjusted or adjusted analyses. In conclusion, higher levels of hsCRP, IL-6, and D-dimer were not associated with ischemic ECG abnormalities. Elevated biomarker levels and ECG abnormalities indicating myocardial ischemia might reflect different risk pathways for cardiovascular disease.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Duprez D.A.
        • Neuhaus J.
        • Kuller L.H.
        • Tracy R.
        • Belloso W.
        • De Wit S.
        • Drummond F.
        • Lane H.C.
        • Ledergerber B.
        • Lundgren J.
        • Nixon D.
        • Paton N.I.
        • Prineas R.J.
        Inflammation, coagulation and cardiovascular disease in HIV-infected individuals.
        PLoS ONE. 2012; 7: e44454
        • Kuller L.H.
        • Tracy R.
        • Belloso W.
        • de Wit S.
        • Drummond F.
        • Lane H.C.
        • Ledergerber B.
        • Lundgren J.
        • Neuhaus J.
        • Nixon D.
        • Paton N.I.
        • Neaton J.D.
        Inflammatory and coagulation biomarkers and mortality in patients with HIV infection.
        PLoS Med. 2008; 5: e203
        • Neuhaus J.
        • Jacobs Jr., D.R.
        • Baker J.V.
        • Calmy A.
        • Duprez D.
        • La Rosa A.
        • Kuller L.H.
        • Pett S.L.
        • Ristola M.
        • Ross M.J.
        • Shlipak M.G.
        • Tracy R.
        • Neaton J.D.
        Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection.
        J Infect Dis. 2010; 201: 1788-1795
        • Plaeger S.F.
        • Collins B.S.
        • Musib R.
        • Deeks S.G.
        • Read S.
        • Embry A.
        Immune activation in the pathogenesis of treated chronic HIV disease: a workshop summary.
        AIDS Res Hum Retroviruses. 2012; 28: 469-477
        • Crow R.S.
        • Prineas R.J.
        • Hannan P.J.
        • Grandits G.
        • Blackburn H.
        Prognostic associations of Minnesota Code serial electrocardiographic change classification with coronary heart disease mortality in the Multiple Risk Factor Intervention Trial.
        Am J Cardiol. 1997; 80: 138-144
        • Liao Y.L.
        • Liu K.A.
        • Dyer A.
        • Schoenberger J.A.
        • Shekelle R.B.
        • Colette P.
        • Stamler J.
        Major and minor electrocardiographic abnormalities and risk of death from coronary heart disease, cardiovascular diseases and all causes in men and women.
        J Am Coll Cardiol. 1988; 12: 1494-1500
        • Soliman E.Z.
        • Prineas R.J.
        • Roediger M.P.
        • Duprez D.A.
        • Boccara F.
        • Boesecke C.
        • Stephan C.
        • Hodder S.
        • Stein J.H.
        • Lundgren J.D.
        • Neaton J.D.
        Prevalence and prognostic significance of ECG abnormalities in HIV-infected patients: results from the Strategies for Management of Antiretroviral Therapy study.
        J Electrocardiol. 2011; 44: 779-785
        • The SMART Study Group
        CD4+ count-guided interruption of antiretroviral treatment.
        N Engl J Med. 2006; 355: 2283-2296
        • Prineas R.
        • Crow R.
        • Zhang Z.
        The Minnesota Code Manual of Electrocardiographic Findings.
        2nd ed. Springer, London2009
        • Asselbergs F.W.
        • van Boven A.J.
        • Stuveling E.M.
        • Diercks G.F.H.
        • Hillege H.L.
        • Kors J.A.
        • de Jong P.E.
        • van Gilst W.H.
        Relation of electrocardiographic abnormalities to levels of serum C-reactive protein.
        Am J Cardiol. 2003; 91: 1358-1360
        • Okin P.M.
        • Roman M.J.
        • Best L.G.
        • Lee E.T.
        • Galloway J.M.
        • Howard B.V.
        • Devereux R.B.
        C-reactive protein and electrocardiographic ST-segment depression additively predict mortality: the Strong Heart Study.
        J Am Coll Cardiol. 2005; 45: 1787-1793
        • Cesari M.
        • Penninx B.W.J.H.
        • Newman A.B.
        • Kritchevsky S.B.
        • Nicklas B.J.
        • Sutton-Tyrrell K.
        • Tracy R.P.
        • Rubin S.M.
        • Harris T.B.
        • Pahor M.
        Inflammatory markers and cardiovascular disease (the Health, Aging and Body Composition [Health ABC] study).
        Am J Cardiol. 2003; 92: 522-528
        • Reilly J.M.
        • Cunnion R.E.
        • Anderson D.W.
        • O'Leary T.J.
        • Simmons J.T.
        • Lane H.C.
        • Fauci A.S.
        • Roberts W.C.
        • Virmani R.
        • Parrillo J.E.
        Frequency of myocarditis, left ventricular dysfunction and ventricular tachycardia in the acquired immune deficiency syndrome.
        Am J Cardiol. 1988; 62: 789-793
        • Mondy K.E.
        • Gottdiener J.
        • Overton E.T.
        • Henry K.
        • Bush T.
        • Conley L.
        • Hammer J.
        • Carpenter C.C.
        • Kojic E.
        • Patel P.
        • Brooks J.T.
        High prevalence of echocardiographic abnormalities among HIV-infected persons in the era of highly active antiretroviral therapy.
        Clin Infect Dis. 2011; 52: 378-386
        • Sloan R.P.
        • McCreath H.
        • Tracey K.J.
        • Sidney S.
        • Liu K.
        • Seeman T.
        RR interval variability is inversely related to inflammatory markers: the CARDIA study.
        Mol Med. 2007; 13: 178-184
        • Aviles R.J.
        • Martin D.O.
        • Apperson-Hansen C.
        • Houghtaling P.L.
        • Rautaharju P.
        • Kronmal R.A.
        • Tracy R.P.
        • van Wagoner D.R.
        • Psaty B.M.
        • Lauer M.S.
        • Chung M.K.
        Inflammation as a risk factor for atrial fibrillation.
        Circulation. 2003; 108: 3006-3010
        • Macfarlane P.W.
        Minnesota coding and the prevalence of ECG abnormalities.
        Heart. 2000; 84: 582-584